Aristea Therapeutics
Dr. O’Connell, a Partner at Novo Ventures, has a proven track record in venture capital investments and corporate development. He was previously Executive Director of Equity and Venture Capital at Bristol Myers Squibb, where he was responsible for managing and operationalizing the $4.5B equity portfolio, comprising both direct equity investments and LP positions in venture funds. While at BMS, he was also a transaction lead in the 2020 acquisition of MyoKardia for $13.1 billion. Dr. O’Connell started in venture investing at OrbiMed Advisors and Arix Bioscience, where he led and supported investments in oncology, orphan diseases, and novel science developing technologies to address unmet medical needs. Dr. O’Connell received his M.D. and Ph.D. at the Tufts University School of Medicine and holds a B.S. from MIT.
This person is not in the org chart
This person is not in any offices
Aristea Therapeutics
Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2 clinical development.